For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| AbobotulinumtoxinA | Participants with moderate to severe Glabellar lines (GL) received AbobotulinumtoxinA (Dysport®), total dose of 50 U (0.25 milliliter \[mL\] total; 10 U \[0.05 mL per injection site\] of study drug into each of the 5 injection sites) at Visits 1, 3, and 5. | 0 | None | 1 | 250 | 107 | 250 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Severe leiomyoma | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 26.1 | View |